Simplex Trading’s Crescent Biopharma CBIO Stock Holding History

Simplex Trading’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,287	Closed	-$48K	–	9039
2025 Q1	$48K	Buy	+2,287	New	+$61.2K	﹤0.01%	5803
2024 Q3	–	Sell	-49	Closed	-$1K	–	8889
2024 Q2	$1K	Sell	49 -62	-56%	-$6.45K	﹤0.01%	8468
2024 Q1	$33K	Buy	111 +105	+1,750%	+$31.4K	﹤0.01%	6664
2023 Q4	$1K	Buy	+6	New	+$933	﹤0.01%	8489
2023 Q1	–	Sell	-10	Closed	-$3K	–	9404
2022 Q4	$3K	Buy	+10	New	+$1.47K	﹤0.01%	8362
2022 Q2	–	Sell	-30	Closed	-$3K	–	10348
2022 Q1	$3K	Sell	30 -667	-96%	-$78.3K	﹤0.01%	9697
2021 Q4	$100K	Buy	697 +496	+247%	+$90K	﹤0.01%	6247
2021 Q3	$46K	Hold	201	–	–	﹤0.01%	7597
2021 Q2	$46K	Buy	201 +200	+20,000%	+$50.9K	﹤0.01%	7742
2021 Q1	$31K	Hold	1	–	–	﹤0.01%	7084
2020 Q4	$39K	Buy	+1	New	+$350	﹤0.01%	6422
2020 Q3	–	Hold	0	–	–	–	7281
2019 Q2	–	Hold	0	–	-$14K	–	7349
2019 Q1	–	Hold	0	–	–	–	5936
2018 Q3	–	Hold	0	–	-$12K	–	7629
2018 Q2	–	Hold	0	–	–	–	6219
2018 Q1	–	Hold	0	–	-$1K	–	6392
2017 Q4	–	Hold	0	–	–	–	5509
2017 Q3	–	Hold	0	–	–	–	4781
2017 Q2	–	Hold	0	–	–	–	5604

Other funds holding CBIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

ACPLP

ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Simplex Trading's CBIO Position: Q3 2026 in Review

Simplex Trading opened a new position in Crescent Biopharma (CBIO) in Q3 2026: 3,413 shares worth $49.8K. The stake represents ﹤0.01% of the portfolio and ranks #6177 among its holdings. This is a return to the name: Simplex Trading previously reported a position in CBIO as recently as Q1 2024.

Simplex Trading first reported a position in CBIO in Q2 2017 and has held it in 21 quarters since. The position peaked at $280K in Q1 2019. 23 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.

Simplex Trading held 3,413 shares of Crescent Biopharma worth $49.8K as of Q3 2026.
Crescent Biopharma was a new Simplex Trading position in Q3 2026.
Crescent Biopharma made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #6177 holding.
Simplex Trading first reported a position in Crescent Biopharma in Q2 2017 and has held it in 21 quarters since.
Simplex Trading's Crescent Biopharma position peaked at $280K in Q1 2019.
23 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.